Argenx

NASDAQ:ARGXBiotech

Netherlands · Est. 2008

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

5 drugs in development

Phase 32

Phase 24

Phase 11

Preclinical1

By Therapeutic Area

top 6

Neurology

538%

Immunology

215%

Nephrology

215%

Hematology

18%

Rare Disease

18%

Infectious Disease

18%

R&D Momentum

67/100

Pipeline Velocity

37/100

Trial Completion Rate

86/100

Pipeline Concentration

22/100

Pipeline Freshness

81/100

Strategic Signals

↗Active in Immunology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 10, 2026

Recruiting

A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants From 12 Years to Less Than 18 Years of Age With Chronic ITP

Jul 9, 2026

Recruiting

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs

Jul 9, 2026

Recruiting

Jul 3, 2026

Active, not recruiting

A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Ocular Myasthenia Gravis

Jul 3, 2026

Active, not recruiting

A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection

Earlier

Jun 30, 2026TrialISA2 to Master Protocol ARGX-999-2-MG-2000 - an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

Jun 30, 2026TrialA Phase 1, Open-Label, Randomized, Single Dose, Parallel-Group Study to Assess the Absolute Bioavailability and Evaluate the Effect of Body Weight on the Pharmacokinetics of Adimanebart SC in Healthy Adult Participants

Mar 20, 2026TrialGLOW-1: Efgartigimod in Systemic Lupus

4 more events

Mar 14, 2026TrialVIVACITY-MG: Efgartigimod SC in Myasthenia Gravis

Mar 4, 2026TrialATLAS: Efgartigimod in Myasthenia Gravis Extension

Mar 2, 2026TrialGLOW-2: Efgartigimod in CIDP

Jan 26, 2026TrialA Study to Assess the Safety of ARGX-124 in Healthy Volunteers

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Founded2008

HQNetherlands

ExchangeNASDAQ:ARGX

Websiteargenx.com

Therapeutic Focus

NeurologyImmunologyInfectious DiseaseHematologyNephrologyOncologyOtherMetabolic & EndocrineRare Disease

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(1 drug)

—

Cardiovascular(1 drug)

Hematology(1 drug)

—

Hematology(1 drug)

Immunology(2 drugs)

—

Immunology(2 drugs)

Infectious Disease(1 drug)

—

Infectious Disease(1 drug)

Nephrology(2 drugs)

—

Nephrology(2 drugs)

Neurology(5 drugs)

—

Neurology(5 drugs)

Rare Disease(1 drug)

—

Rare Disease(1 drug)

Regulatory

Regulatory Timeline

20211 event

FDADec 17

Vyvgart — VYVGART

Application BLA761195 (BLA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)